What’s Of Interest
Investigator Resources
Investigator Information and How to Contact Us
Perspectives by Colleagues Video
Emerging Approaches in Oncology
Cachexia/Cancer Supportive Care Study
Emerging Approaches in Oncology
The Role of Cyclin-Dependent Kinases (CDK) 4 & 6 in Normal and Tumor Cells
BCMA / CD3 Bispecific Ab PF-06863135 Background, Rationale & Mode of Action
Scheduled Events
Oral Presentations
Session title:
Circulating Tumor DNA: A Versatile Analyte to Guide the Care of Patients With Lung Cancer
Description: Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib: analysis from the CROWN study
Abstract No: 9011
On-Demand Session Release Date and Time:
6/4/2021, 9:00 AM-10:15 AM EDT
Session title:
Dr. Bernard Fisher Memorial Annual Clinical Science Symp: A Focus on Equity in Breast Cancer Care
Description: PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation
Abstract No: 1012
On-Demand Session Release Date and Time:
6/4/2021, 9:00 AM-10:15 AM EDT
Session title:
Breast Cancer—Metastatic
Description: Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses
from PALOMA-3
Abstract No: 1000
Session Date and Time:
6/5/2021, 1:30 PM-4:30 PM EDT
Session title:
Breast Cancer—Local / Regional / Adjuvant
Description: Neoadjuvant Talazoparib in Patients with Germline BRCA1/2 (gBRCA1/2) Mutation-positive, Early HER2-negative Breast Cancer (BC): Results of a Phase 2 Study
Abstract No: 505
Session Date and Time:
6/6/2021, 8:00 AM-11:00 AM
Session title:
Melanoma/Skin Cancers
Description: 5-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma
Abstract No: 9507
Session Date and Time:
6/6/2021 8:00 AM – 11:00 AM EDT
Session title:
Hematologic Malignancies—Plasma Cell Dyscrasia
Description: Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)–CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Abstract No: 8006
Session Date and Time:
6/8/2021, 8:00 AM – 11:00 AM EDT
Live Office Hours
Breast/Prostate
June 4, 2021 10:00 a.m. - 11:00 a.m. EDT
June 5, 2021 4:30 p.m. - 5:30 p.m. EDT
June 6, 2021 11:00 a.m. - 12:00 p.m. EDT
June 7, 2021 3:00 p.m. - 4:00 p.m. EDT
June 8, 2021 1:00 p.m. - 2:00 p.m. EDT
Other Tumor Types
June 4, 2021 10:00 a.m. - 11:00 a.m. EDT
June 5, 2021 10:00 a.m. - 11:00 a.m. EDT
June 6, 2021 11:00 a.m. - 12:00 p.m. EDT
June 7, 2021 10:00 a.m. - 11:00 a.m. EDT
June 8, 2021 11:00 a.m. - 12:00 p.m. EDT
